Vahideh Keyvani, Samaneh Mollazadeh, Espanta Riahi, Reihaneh Alsadat Mahmoudian, Masoomeh Tabari, Elmira Lagzian, Elnaz Ghorbani, Hamed Akbarzade, Amir-Sadra Gholami, Ibrahim Saeed Gataa, Seyed Mahdi Hassanian, Gordon A Ferns, Majid Khazaei, Amir Avan, Kazem Anvari
Gynecological cancers (GCs), ovarian, cervical, and endometrial/uterine cancers, are often associated with poor outcomes. Despite the development of several therapeutic modalities against GCs, the effectiveness of the current therapeutic approaches is limited due to their side effects, low therapeutic index, short halflife, and resistance to therapy. To overcome these limitations, nano delivery-based approaches have been introduced with the potential of targeted delivery, reduced toxicity, controlled release, and improved bioavailability of various cargos...
March 18, 2024: Current Pharmaceutical Design